Lupin ties up with Sandoz to commercialise biosimilar product

Lupin has partnered with Sandoz Group AG to commercialize its biosimilar ranibizumab across multiple regions, with Sandoz handling commercialization in the EU (excluding Germany), Switzerland, Norway, Australia, Hong Kong, Vietnam, and Malaysia. Lupin will manufacture the product and manage regulatory submissions. Sandoz also gains exclusive rights for commercialization in Canada.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/9LHTCSq
via IFTTT